Loading grant details…
Strengthening the European Chain of sUpply for next generation medical RadionuclidEs
| Funder | European Commission |
|---|---|
| Recipient Organization | Narodowe Centrum Badan Jadrowych |
| Country | Poland |
| Start Date | Oct 01, 2022 |
| End Date | Sep 30, 2025 |
| Duration | 1,095 days |
| Number of Grantees | 18 |
| Roles | Participant; Associated Partner; Coordinator |
| Data Source | European Commission |
| Grant ID | 101061230 |
Grant Description
SECURE project aims to make a major contribution to the sustainability of medical isotope production and its safe application in Europe.
It is focusing on promising developments in the design of irradiation targets, production routes for existing and new isotopes in nuclear therapy and diagnostics.
Isotopes critical in the success of nuclear medicine are selected and research activities are identified to address some of the major challenges in securing its future availability, with the objectives:1.to remove critical barriers along the production of its selected alpha and beta emitting isotopes that restrict a sustainable production, 2.to develop a framework of guidance and recommendations that enables exploring the full clinical potential of alpha and beta particle therapy and its safe application 3.to provide important lessons learned that act as a demonstration case for addressing issues in upscaling and sustained isotope production.At present, Ra-223 is the only radiopharmaceutical which has been granted marketing authorization to treat adults with prostate cancer.
This has paved the way for a wider use of other alpha emitters such as Ac-225 or Bi-213.
The expected demand of nuclear medicine for novel alpha emitters and beta- emitters requires re-evaluation of their production methods and inventories of target materials and parent radionuclides.
The ambition of SECURE consortium is to identify and efficiently use the current resources for new radionuclides, in particular for alpha emitters and the relevant beta emitting theranostic radionuclides.
The development of alternative technologies for production of such therapeutic radionuclides for improved patient treatment requires multidisciplinary scientific and technological knowledge including physics, chemistry, material science, machining of target materials, chemistry, biology and radiobiology, radiopharmacy and nuclear medicine.
All this chain of expertise is present in SECURE consortium.
All Grantees
Institut Max Von Laue - Paul Langevin; Institut Jozef Stefan; Clust Er Industrie Della Salute E Del Benessere; National Nuclear Laboratory Limited; Universite de Bretagne Occidentale; Budapesti Muszaki Es Gazdasagtudomanyi Egyetem; Narodowe Centrum Badan Jadrowych; Evalion Sro; Hun-Ren Energiatudomanyi Kutatokozpont; Agenzia Nazionale Per Le Nuove Tecnologie, L'Energia E Lo Sviluppo Economico Sostenibile; Studiecentrum Voor Kernenergie / Centre D'Etude de L'Energie Nucleaire; European Nuclear Education Network; Nuclear Research and Consultancy Group; Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori - Irst Srl; Clusterul Regional Inovativ de Imagistica Moleculara Si Structurala Nord-Est (Imago-Mol); Univerzitetni Klinicni Center Ljubljana; European Federation of Organisations for Medical Physics; Jrc -Joint Research Centre- European Commission
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
